In addition to PTEN-null tumours, p110β has been pursued as a target for antithrombotic therapy [16], and there is also growing evidence that p110β inhibitors could have significant therapeutic potential in autoimmune diseases [17-19]. The gene discussed is PTEN; the disease is neoplasm.